ESMO Sarcoma and Rare Cancers 2023 | Neoadjuvant versus adjuvant treatment chemoradiotherapy in sarcoma

Antonia Digklia, MD, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, offers her perspective on whether neoadjuvant or adjuvant chemoradiotherapy is more optimal in the treatment of patients with sarcoma. Dr Digklia highlights that this decision is primarily based on the patients’ comorbidities and tolerability of treatment; however retrospective data has swayed her opinion in favor of neoadjuvant therapy as it has been shown not to increase toxicity in these patients. This interview took place at the ESMO Sarcoma and Rare Cancers Congress 2023 in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.